InventisBio Co (SHSE:688382) ROCE % : -18.43% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is InventisBio Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InventisBio Co's annualized ROCE % for the quarter that ended in Mar. 2024 was -18.43%.

InventisBio Co ROCE % Historical Data

The historical data trend for InventisBio Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InventisBio Co ROCE % Chart

InventisBio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-41.42

-32.84

-13.38

InventisBio Co Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial												-22.56	-8.38	-14.22	-8.59	-18.43

InventisBio Co ROCE % Calculation

InventisBio Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-283.792	/	( ( (2347.827 - 111.015)	+	(2162.272 - 158.274) )	/ 2 )
	=	-283.792	/	( (2236.812	+	2003.998)	/ 2 )
	=	-283.792	/	2120.405
	=	-13.38 %

InventisBio Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-363.46	/	( ( (2162.272 - 158.274)	+	(2076.77 - 136.108) )	/ 2 )
	=	-363.46	/	( ( 2003.998	+	1940.662 )	/ 2 )
	=	-363.46	/	1972.33
	=	-18.43 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

InventisBio Co (SHSE:688382) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InventisBio Co ROCE % Related Terms

Thank you for viewing the detailed overview of InventisBio Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

InventisBio Co (SHSE:688382) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InventisBio Co Ltd (SHSE:688382) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 4, Lane 67, Li Bing Road, Room 210, Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

http://www.inventisbio.com

InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.

InventisBio Co (SHSE:688382) Headlines

No Headlines